Abstract:Polo-like kinase 1 (Plk1) belongs to a subfamily of Ser/ Thr protein kinases, collectively termed polo-like kinases (Plks). A growing body of evidence suggests that Plk1 plays important roles during multiple stages of M-phase progression and, as a result, in cell proliferation. In a series of preclinical studies, PLK1 has been validated as a cancer target. This has prompted many research scientists to develop selective PLK1 inhibitors for the treatment of cancer. The recent strategy employed in PLK1 inhibition involves the designing of small molecule inhibitors that targets the classical ATP-binding site of PLK1. Purpurogallin (PPG) and poloxin have been reported as inhibitors of the polo-box domain (PBD) of human polo-like kinase 1. Recently, new generation of PLK1 inhibitors targeting the second druggable domain of PLK1, the polo box domain, is currently being tested preclinically. We propose to design and develop 1, 3-thiazolidin-4-ones which could inhibit PLK1 for potent anticancer and anti-inflammatory activities. The 1, 3-thiazolidin – 4-ones could show anticancer and anti-inflammatory potential through inhibition of polo-like kinase 1 (PLK1) and cyclooxygenase-2 (COX 2) via NF-Kb (nuclear factor kappa-light- chain-enhancer of activated B cells) protein. Molecular docking of a set of ligands was performed using Vlife MDS 4.4 software. The 3D ligand protein complex structure of Polo Like Kinase 1 (2rku) was obtained from the protein database bank (RCSB-PDB) and processed for protein preparation and optimization. The computational studies suggest that aromatic group with non-polar electronegative substituents at second position and nitro-heterocycle either directly or through amide linkage at third position of the 1, 3-thiazolidin – 4-ones could result in better anticancer compound through inhibition of enzyme polo-like kinase 1.

Designed Inhibitor for Nuclear Localization Signal of Polo-Like Kinase 1 Induces Mitotic Arrest.

Discovery of Novel Polo-Like Kinase 1 Polo-Box Domain Inhibitors to Induce Mitotic Arrest in Tumor Cells.

Involvement of Polo-like Kinase 1 (plk1) in Mitotic Arrest by Inhibition of Mitogen-activated Protein Kinase-Extracellular Signal-regulated Kinase-Ribosomal S6 Kinase 1

Design, synthesis and biological evaluation of phosphopeptides as Polo-like kinase 1 Polo-box domain inhibitors

Discovery of Non-ATP-Competitive Inhibitors of Polo-like Kinase 1.

Dissecting the phenotypes of Plk1 inhibition in cancer cells using novel kinase inhibitory chemical CBB2001

Molecular Docking Studies of 1, 3- Thiazolidin-4-Ones as Potential Human Polo Like Kinase 1 (Plk 1) Inhibitors

Involvement of Polo-like Kinase 1 (plk1) in Mitotic Arrest by Inhibition of Mitogen-activated Protein Kinase-Extracellular Signal-regulated Kinase-Ribosomal S6 Kinase 1 (MEK-ERK-RSK1) Cascade*

Identification of novel and selective non-peptide inhibitors targeting the polo-box domain of polo-like kinase 1

Identification of Nitroimidazole-Oxime Derivatives Targeting the Polo-Box Domain of Polo-Like Kinase 1.

Exploring Novel PLK1 Inhibitors Based on Computational Studies of 2,4-Diarylaminopyrimidine Derivatives

Identification of naphthalimide-derivatives as novel PBD-targeted polo-like kinase 1 inhibitors with efficacy in drug-resistant lung cancer cells

Inhibitors of the PLK1 polo-box domain: drug design strategies and therapeutic opportunities in cancer

Plk1 As A Potential Drug Target in Cancer Therapy

Structure-based discovery of 1-(3-fluoro-5-(5-(3-(methylsulfonyl)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)phenyl)-3-(pyrimidin-5-yl)urea as a potent and selective nanomolar type-II PLK4 inhibitor

Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer.

Design, Synthesis and Biological Evaluation of Thienopyridinones As Chk1 Inhibitors

Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment

Aromatic Diacylhydrazine Derivatives As a New Class of Polo-Like Kinase 1 (PLK1) Inhibitors.

A novel anti-tumor inhibitor identified by virtual screen with PLK1 structure and zebrafish assay.

Discovery of Inhibitors of Aurora/PLK Targets As Anticancer Agents.